P/E ratio for bluebird bio (BLUE)
P/E ratio as of June 2024 (TTM): -0.8780
According to bluebird bio 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.878039. At the end of 2022 the company had a P/E ratio of -1.93.
P/E ratio history for bluebird bio from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.93 | 131.22% |
| 2021 | -0.8360 | -70.32% |
| 2020 | -2.82 | -29.08% |
| 2019 | -3.97 | -34.04% |
| 2018 | -6.02 | -60.01% |
| 2017 | -15.1 | 166.04% |
| 2016 | -5.66 | -34.68% |
| 2015 | -8.67 | -74.04% |
| 2014 | -33.4 | 640.36% |
| 2013 | -4.51 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 15.0 | -1,812.87% | 🇫🇷 France |
 Merck MRK | 68.4 | -7,885.53% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | -0.3786 | -56.88% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 GlycoMimetics
GLYC | -0.4215 | -51.99% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 95.7 | -10,993.75% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.